Immunic Inc (NAS:IMUX)
$ 1.27 -0.02 (-1.55%) Market Cap: 114.40 Mil Enterprise Value: 20.02 Mil PE Ratio: 0 PB Ratio: 1.37 GF Score: 41/100

Q4 2021 Immunic Inc Earnings Call Transcript

Feb 24, 2022 / 01:00PM GMT
Release Date Price: $10.72 (-9.15%)
Jessica Breu
Immunic, Inc. - Head of IR & Communications

Good morning, and welcome to Immunic's Fourth Quarter and Year-End 2021 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's call.

Speaking on today's call are Dr. Daniel Vitt, our Chief Executive Officer and President; as well as Glenn Whaley, our Vice President Finance and Principal Financial and Accounting Officer. For the Q&A session of today's call, we also have our Chief Medical Officer, Dr. Andreas Muehler on the call. (Operator Instructions) And this event is being recorded. (Operator Instructions)

Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with a similar meaning. And such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here.

Please note that these forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot